Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > MHLW Expert Panel on Comprehensive Measures for Pharmaceuticals
MHLW Expert Panel on Comprehensive Measures for Pharmaceuticals
-
Expert Panel Agrees on Need for Generic Industry Shakeup, Company Criteria Floated
February 16, 2023
-
5-Year Mandatory Stable Supply Rule for Generics under Scrutiny: Expert Panel
February 16, 2023
-
Experts Doubt Necessity of Policy Intervention for LLP-Dependent Companies
January 27, 2023
-
Expert Panel Member Alarmed by Stagnation of Biosimilar Business in Japan
January 27, 2023
-
Experts Call for Deregulations for Orphan Support, English Dossiers to Foster Biotech Ecosystem
January 16, 2023
-
Add New Evaluation Elements in Granting Launch Premiums: Expert Panel
December 12, 2022
-
Market Expansion Re-Pricing Has Gone Overboard with Spillover Rule, Experts Say
December 12, 2022
-
Revisit PMP Company Criteria to Support Innovation from Foreign Biotechs: Experts
December 12, 2022
-
Experts Call for New Drug Pricing Rule for Innovative Medicines, No Objections Raised
December 12, 2022
-
Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers
October 31, 2022
-
Think Tanks Propose New Pricing Methods for Innovative Meds, Multi-Faceted Evaluations
October 28, 2022
-
Policy Veterans’ Group Advocates Drug Reimbursement at Actual Purchase Prices
October 28, 2022
-
Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
-
Nearly 700 Key Drugs Found to Be Unprofitable Due to Inflation, FX: Survey
October 24, 2022
-
Is New Expert Panel All about Drug Pricing System? Asks Chair
October 24, 2022
-
Experts Call for Debate on Scope of Health Coverage, “Exit Rule” for Unnecessary Meds
October 24, 2022
-
NHI-Market Price Gap at 20-Plus-Outlet Pharmacies 1.8 Times Larger vs. Small Hospitals
October 14, 2022
-
Experts Urge MHLW to Present Detailed Data on Generic Manufacturing Costs
October 13, 2022
-
Ways to Resolve Drug Lag/Loss, Fuel Development in Japan Up for Debate: MHLW Panel
October 13, 2022
-
Panel Members Want More Data on Allocation of NHI-Market Price Margins
October 13, 2022
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…